Defining gene transfer before expecting gene therapy: putting the horse before the cart.
Pislaru
Sorin
S
Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA.
Janssens
Stefan P
SP
Gersh
Bernard J
BJ
Simari
Robert D
RD
D001711:Biotransformation; D002318:Cardiovascular Diseases / Q000628:therapy*; D016228:Endothelial Growth Factors / Q000235:genetics / Q000627:therapeutic use; D018014:Gene Transfer Techniques / Q000009:adverse effects; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods / Q000639:trends; D005822:Genetic Vectors / Q000009:adverse effects / Q000627:therapeutic use; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006801:Humans; D008222:Lymphokines / Q000235:genetics / Q000627:therapeutic use; D018919:Neovascularization, Physiologic / Q000235:genetics; D010599:Pharmacokinetics; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors